NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization52.66 mln
Float47.32 mln
Earnings Date08/05/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
24
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-88.58
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Founded in 1998 and headquartered in Austin, Texas, Filana Therapeutics Inc. is a medical research company working to fight brain-wasting diseases. Its most advanced treatment, simufilam, is currently in a Phase 3 trial for Alzheimer's disease, while a separate early-stage tool called SavaDx aims to identify the condition using just a small blood sample. The company was previously called Cassava Sciences Inc. before adopting its current name in March 2026.
